In a newly published study, researchers at Karolinska Institutet show that the shortening of the telomeres – the caps at each end of the chromosomes in our cells – can be linked statistically to the active mechanism responsible for Alzheimer’s disease. However, the effect is small and telomere length cannot yet be used to assess disease risk at an individual level. The results are presented in the journal JAMA Neurology.
Every cell in our body contains our entire genome, packed into the nucleus in the form of 46 chromosomes. Every time a cell divides, the telomeres at the tips of the chromosomes become slightly shorter until they reach a critical length, at which point the cell dies. Just where this critical threshold goes depends on the individual, partly because the telomeres are of different lengths to start with, and partly because in some people the telomeres shorten more on cell division than in others. The shortening process takes place when we age, but previously telomere length was only used as a marker for biological ageing.
For the first time, a group of scientists at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet has shown that telomere length is causally linked to the risk of developing Alzheimer’s disease.
“That there’s some kind of link between telomere length and the risk of Alzheimer’s disease is nothing new in itself, but it was thought that it was down to other underlying commonalities,” says principal investigator Dr Sara Hägg, docent of molecular epidemiology. “In this study we’ve been able to show that the telomeres are involved in the actual active mechanism behind the development of the disease, which is completely new and very interesting.”
The entire genome
To arrive at their results, the researchers used data from studies that identified gene variants linked to telomere length and to Alzheimer’s disease by examining the entire genome. By using a special study design, they were then able to show statistically the presence of a causal link between short telomeres and a higher risk of Alzheimer’s disease. The researchers stress, however, that since the telomere process is so complex, nothing can be said about the degree of an individual person’s risk from the mere measurement of their telomeres.
“What’s more, the effects are very small,” adds Dr Hägg. “But from a biological perspective, they’re very interesting.”
Funding: The study was financed with grants from various bodies, including the Loo and Hans Österman Foundation, FORTE, the Swedish Research Council, KID-grant from Karolinska Institutet for doctoral education, and the Foundation for Geriatric Diseases at Karolinska Institutet.
Source: Katarina Sternudd – Karolinska Institute
Image Source: The image is credited to Reinhard Stindl and is licensed CC BY-SA 3.0
Original Research: Abstract for “Telomere Length Shortening and Alzheimer Disease—A Mendelian Randomization Study” by iqiang Zhan, MD; Ci Song, PhD; Robert Karlsson, PhD; Annika Tillander, PhD; Chandra A. Reynolds, PhD; Nancy L. Pedersen, PhD; and Sara Hägg, PhD in JAMA Neurology. Published online October 2015 doi:10.1001/jamaneurol.2015.1513
Telomere Length Shortening and Alzheimer Disease—A Mendelian Randomization Study
This study explores the causal effect of telomere length on Alzheimer disease by applying the mendelian randomization method to summary genome-wide association study data.
Telomeres are sequences of repetitive nucleotides at the end of the chromosomes, which protect them from fusion with neighboring chromosomes.1 Observational studies have found associations between shorter telomeres and Alzheimer disease (AD).2 However, these studies could have residual confounding or reverse causation, making it difficult to draw conclusions on whether telomere length (TL) is causally associated with AD. For the past decades, instrumental variable (IV) analysis has been developed for assessing causality using genetic variants in epidemiological research under the name of mendelian randomization (MR).3 In the present study, we investigated the causal effect of TL on AD by applying the MR method to summary genome-wide association study (GWAS) data from Codd et al4 and from the International Genomics of Alzheimer’s Project Consortium.5
“Telomere Length Shortening and Alzheimer Disease—A Mendelian Randomization Study” by iqiang Zhan, MD; Ci Song, PhD; Robert Karlsson, PhD; Annika Tillander, PhD; Chandra A. Reynolds, PhD; Nancy L. Pedersen, PhD; and Sara Hägg, PhD in JAMA Neurology. Published online October 2015 doi:10.1001/jamaneurol.2015.1513